A Randomized, Double Blind, Placebo Controlled Study of the Effects of Etanercept in Children Presenting With Kawasaki Disease

Trial Profile

A Randomized, Double Blind, Placebo Controlled Study of the Effects of Etanercept in Children Presenting With Kawasaki Disease

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Etanercept (Primary) ; Aspirin; Immune globulin
  • Indications Mucocutaneous lymph node syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 May 2017 Planned End Date changed from 1 Oct 2016 to 1 Jul 2017.
    • 01 May 2017 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.
    • 13 Oct 2016 Planned End Date changed from 1 Jul 2016 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top